Current clinical trials investigating novel agents and combination therapies for myelofibrosis (MF) were presented during the ninth annual Society of Hematologic Oncology meeting. These evolving data have implications for advanced practice, where the focus is on patient education and managing disease-related symptoms and treatment toxicities. Currently, ruxolitinib (Jakafi) and fedratinib (Inrebic) are two Janus kinase inhibitors (JAKi) approved for front-line MF therapy. Despite improved outcomes driven by JAKi, there exists unmet cardinal needs for subsets of MF patients who either progress on or are resistant to or intolerant of ruxolitinib, have disease-related cytopenias, have high-risk disease, or have disease-related symptoms affecting quality of life.
展开▼
